Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference\n\n\n\n TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”) a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management will attend the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025.\n \n\n Quantum BioPharma Head of Finance and M&A Jason Sawyer will attend the Sidoti Micro-Cap Conference on May 21 and the A.G.P. Virtual Healthcare Conference on May 22, where Mr. Sawyer is scheduled to host one-on-one meetings with institutional investors at both events and host a webcast presentation at the Sidoti Micro-Cap Conference.\n \n\n\n Sidoti Micro-Cap Conference\n \n\n Date: Wednesday, May 21, 2025\n \n Format: Presentation & Virtual 1x1 Meetings\n \n Presentation: 9:15-9:45 AM ET in Track 1\n \n Webcast: Click\n \n here\n \n\n Attendee: Head of Finance and M&A Jason Sawyer\n \n Conference Website: Click\n \n here\n \n\n\n\n A.G.P. Virtual Healthcare Conference\n \n\n Date: Thursday, May 22, 2025\n \n Format: Virtual 1x1 Meetings\n \n Attendee: Head of Finance and M&A Jason Sawyer\n \n Conference Website: Click\n \n here\n \n\n\n For more information on the Sidoti Micro-Cap Conference, A.G.P. Virtual Healthcare Conference, or to schedule a one-on-one meeting with Quantum BioPharma management, please contact your conference representative or you may also email your request to\n \n [email protected]\n \n or call Chris Tyson at (949) 491-8235.\n \n\n\n About Quantum BioPharma Ltd.\n \n\n\n Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“\n \n Lucid\n \n ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation,...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B